Avalyn Pharma announced a $345 million upsized IPO, boosting cash reserves to $123.1 million as of March 2026, sufficient to fund operations into 2029. The company is advancing inhaled therapies for pulmonary fibrosis, with Phase 2b enrollment for AP01 on track to complete mid-2026 and topline data expected in late 2027. AP02 Phase 2 trial enrollment is underway, with results anticipated by the end of 2027, and a Phase 1 trial for AP03 is planned by the end of 2026. These programs aim to improve treatment tolerability and efficacy for serious lung diseases, potentially redefining care standards.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
